IOL Chem and Pharma Q4 FY25 earnings call
In brief
IOLCP Q4 FY25 EBITDA margin up 141bps at 12.7%; guides FY26 margin >15% on 10-15% revenue growth
- Management's tone
- Mixed
- What was said
- Leaned positive
- Guidance
- First guidance issued
- Analyst pushback
- Medium
- Stock, next session
- −2.76% (Nifty 50 −1.05%)
- Q4 FY25 EBITDA margin expanded 141bps YoY to 12.7% on INR67cr EBITDA, with PAT of INR31.6cr at 5.9% margin.
- Mgmt guides FY26 EBITDA margin above 15% backed by 10-15% revenue growth across products.
- Commissioned fully backward-integrated Paracetamol unit at Barnala (INR155cr, 10,800 MTPA), funded via internal accruals.
- Received China CDE approval for Ibuprofen; targets scaling export share from ~27% to 40-45% in next 2 years.
- FY26 capex plan of INR150-200 crores; acquired 101 acres along Chandigarh-Bathinda Highway for greenfield expansion.
An AI read of the company's transcript · the filing
The numbers
The quarter, Q4 FY25
| This quarter | A year ago | Last quarter | Margin | |
|---|---|---|---|---|
| Revenue | ₹528 cr | +4.7% | +0.9% | |
| EBITDA (excl. other income) | ₹62.8 cr | +26.7% | +33.9% | 11.9% (9.8% a year ago) |
| Net profit | ₹31.4 cr | +13.8% | +53.0% | 6% (5.5% a year ago) |
| EPS (₹) | ₹1.07 | −77.3% | −69.4% |
From the company's filed results for the quarter ended 31 Mar 2025 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.
Where management's figures differ from the filing
- EBITDA (Q4 FY25): said ~INR67 crores, +17% YoY, margin 12.7% (as stated on the call); filed ₹62.75 cr (+26.7% YoY, margin 11.9%) excluding other income. Mgmt's Q4 EBITDA includes other income of ₹4.53 cr (₹62.75 + ₹4.53 ≈ ₹67 cr). Filed EBITDA excludes other income, hence the gap and margin difference.
What moved the numbers, as management explained it
- Volume growth in Ibuprofen and most non-Ibu APIs (Clopidogrel, Fenofibrate, Pantoprazole) drove Q4 improvement, partly offset by softer Paracetamol demand.
- Power and fuel costs fell sharply as rice husk fuel prices dropped drastically in FY25.
- Pricing pressure persisted in pharma APIs due to global oversupply and aggressive pricing from new entrants, especially in India.
- Higher depreciation from recent capex (incl. INR155cr Barnala Paracetamol unit) pressured reported PAT; cash PAT still grew ~15% YoY. (one-off)
- Mgmt's INR67cr Q4 EBITDA includes other income of INR4.53cr; filed EBITDA excluding other income is INR62.75cr. (accounting)
The numbers management led with
- Paracetamol capacity post-commissioning: 10,800 MTPA
- Paracetamol capex: INR155 crore funded entirely from internal accruals
- FY26 capex plan: INR150-200 crore including growth, infrastructure and automation
- Export revenue share: 27% currently, target 40-45% over medium term
- Greenfield land acquisition: 101 acres along Chandigarh-Bathinda Highway
Guidance
Guidance on this call
| What | For | What management said | Filed |
|---|---|---|---|
| Consolidated EBITDA margin | FY26 | Expecting more than 15% EBITDA margin in the current year (FY26) | 11.1%, below the range |
| Consolidated revenue growth | FY26 | Expecting 10% to 15% growth in revenue from all the products in FY26 | 11.5%, within the range |
| FY26 capex | FY26 | Planned INR150 crores to INR200 crores capex in the current year | — |
| Export share of revenue | FY26-FY27 | Aim to achieve export revenue of around 40% to 45% over the medium term / next 2 years | — |
| Chemicals EBITDA margin target | FY26 | Approximately 10% is the better margin for chemical sector | — |
| Peak revenue from existing capacity | — | Peak revenue from existing capacity around INR2,700 crores to INR2,800 crores | — |
Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.
Guided on earlier calls, and what was filed
| What | For | Guided | Filed |
|---|---|---|---|
| Company revenue growth | FY25 | 10–12% (on the Q4 FY24 call) | -2.5%, below the range |
| EBITDA margin | FY25 | 12–15% (on the Q4 FY24 call) | 9.7%, below the range |
| PAT margin | FY25 | 7–8% (on the Q4 FY24 call) | 4.9%, below the range |
Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.
The business
By business
API (Pharmaceuticals)
Q4 FY25 saw improved traction in Ibuprofen and stable demand across most of the broader API basket; Paracetamol demand lagged. Non-Ibu portfolio share rose to ~34% of API revenues.
Q4 Ibu:non-Ibu revenue split 65:35 · Non-Ibu ~34% of API revenues · Paracetamol capacity 10,800 MTPA · Clopidogrel capacity expanded 33% · 16 DMFs and 19 CEPs filed · Export revenues ~27% of total
Outlook: China CDE approval opens new market for Ibuprofen; export share target 40-45% in next 2 years.
Chemicals
Q4 FY25 chemicals EBITDA margin rose to 6% from 3% in FY24 on higher volumes of ethyl acetate and acetic anhydride; most chemical output is captive for API manufacturing.
Q4 FY25 chemicals EBITDA margin 6% vs FY24 3% · Chemical export share rose to ~18% in FY25 from 10-12% earlier
Outlook: Ethyl acetate prices seen as bottomed out; targets ~10% chemicals EBITDA margin.
Balance sheet, capex and funding
- Net debt-to-equity ratio 0.09 at FY25 end (working capital borrowing included), reflecting minimal leverage and strong internal accruals.
- FY26 capex plan of INR150-200 crores covering growth capex, infrastructure and automation.
- INR155 cr Paracetamol unit at Barnala commissioned in FY25, funded entirely via internal accruals.
- Acquired 101 acres of land along Chandigarh-Bathinda Highway for future greenfield expansion (industrial, environmental and NHI clearances progressing into FY26).
- Full year FY25 cash PAT of INR185 crores underscores strong cash generation.
- Ample headroom cited to fund future growth, pursue expansion and long-term strategic initiatives.
The industry, as management sees it
Management views pharmaceutical demand as stable but pressured by global oversupply and aggressive Indian pricing; chemical prices for ethyl acetate seen as bottoming out with stable raw material costs; China CDE approval cited as a key regulatory milestone for the global API market.
Risks management named
- Paracetamol demand was below expectations in FY25 with muted pricing recovery
- Higher depreciation from recent capital investments weighed on reported PAT
- U.S. FDA inspection timing remains uncertain — under agency prerogative, not company control
- Global API pricing pressure persists despite management's view that prices have bottomed out
- Reduction in other expenses partly driven by lower rice-based fuel prices — sustainability not guaranteed
Q&A
Q&A spanned 12 exchanges dominated by margin recovery, export scaling, and capex productivity questions. The sharpest pushback came from Akshay Kothari on capex-to-revenue productivity, which drew a defensive response on industry price decline. Surabhi and Sahil Vohra pressed on segment margin differentials and the path to recovery, with management offering directional language rather than hard numbers. The clearest new information was the first-ever FY26 guidance of 10-15% revenue growth and >15% EBITDA margin.
Not answered directly
- Levetiracetam market size
- Specific Ibuprofen volume to China
- Chemical margin target timing to 10%
- USFDA inspection timing
- Backward integration product specifics
- Edoxaban patent status
Asked for a number, answered without one
- Market size of Levetiracetam molecule: Mgmt said it does not have any idea of the market size as of now.
- Exact volume vs value growth split for Q4 FY25: Rakesh Mahajan said exact numbers are very difficult to give on the call; cited volume growth in Ibuprofen and non-Ibu (except Paracetamol) qualitatively.
- China vs Europe margin differential for Ibuprofen exports: Kushal Kumar Rana said it is very difficult to comment on price; characterised China as 'almost same' as Europe but dependent on order specifics.
Every question, with its answer
1. Levetiracetam outlook and geography
Vivek Patel, Ficom Family Office
Question. How has Levetiracetam performed over the last few quarters and how do you see the market for this molecule over the next 1-2 years? Any geography expected to outperform — US, Europe, Africa, Latin America? Any estimate of the molecule's market size?
Answer, Kushal Kumar Rana, Director Works. Capacity has been enhanced for Levetiracetam; approaching new customers and filed US DMF; expecting good volumes. CEP secured, so Europe is the primary target followed by US and India in parallel; ANVISA approval opens Brazil. Market size estimate not available as of now.
Follow-up. Any estimate of the molecule's market size?
Answer. No, as of now we don't have any idea.
Not answered directly.
2. China Ibuprofen opportunity and chemical margin recovery
Aryan Jain, Lotus Wealth
Question. What scale of Ibuprofen exports to China can we expect post the CDE approval and will it have material revenue impact? When can we get price realisations in chemicals — can margins move to 14-15%?
Answer, Kushal Kumar Rana, Director Works. China is a new market with good volumes for Ibuprofen and derivatives; have started touching customers there. Forecast will firm up over time. On chemicals, merchant sales are mainly ethyl acetate — prices stable for last 2-3 quarters; raw material prices also stable. Internal efficiencies and cost reduction are the primary levers; no firm margin guidance beyond that.
Follow-up. Can we get to 14-15% margins going forward?
Answer. Primarily working on internal efficiencies and cost reduction; prices are linked to raw materials but various mechanisms being developed to lower production cost.
Not answered directly.
3. Volume vs value growth and segment margins
Surabhi, NV Alpha
Question. What was the volume growth vs value growth in Q4 and FY25? What is the margin differential between non-Ibu API segment and Ibuprofen? How do China margins compare with Europe and domestic?
Answer, Abhay Raj Singh, SVP & Company Secretary. Ibu and Clopidogrel, Pantoprazole, Fenofibrate saw volume turnover above plan; Paracetamol demand contracted. Exact numbers difficult to give on call. IOL is a backward-integrated, cost-efficient Ibuprofen player with 85-90% capacity utilisation — sustainable margins. Non-Ibu also registered volume growth in Q4. On China vs Europe pricing, premature to comment until customer realisations come in; directionally similar.
Follow-up. Is China more margin accretive than Europe?
Answer. In general, almost same, but depends on the requirement and customers order to order.
Partly answered.
4. Peak revenue, capex productivity and chemical margin trajectory
Akshay Kothari, Envision Capital
Question. What is peak revenue from existing capacity? Is the INR1,000 cr chemical revenue mainly ethyl acetate? Gross block has more than doubled over 5 years while revenue growth has been modest — what went wrong and what are future capex plans? When can chemical segment margins reach healthy levels like 10%?
Answer, Abhay Raj Singh, SVP & Company Secretary. Peak revenue from existing capacity at current prices is INR2,700-2,800 cr. Chemical revenue is ~80% ethyl acetate plus acetic anhydride; IBB is minor. Major capex was on pharma side and only acetic anhydride on chemicals side; revenue subdued because API prices have declined ~25% over 5 years. Kushal Rana added: 10% is a better margin for chemical sector — achieved 6% in Q4 FY25 vs 3% in FY24, hopeful of crossing 6% in current year.
Follow-up. Can chemical segment margins go to 10%?
Answer. In Q4 FY25 we achieved 6% chemical EBITDA vs 3% in FY24; going forward to 10% — hopefully in the current year we will achieve more than 6%.
Partly answered.
5. Pharma margin recovery and export scaling strategy
Sahil Vohra, M&S Associates
Question. Pharma EBIT fell sharply from INR174 cr to INR126 cr in FY25 — is the margin pressure structural or temporary, and is Q4 a sign of recovery? What specific strategies and geographies will help lift export share from 27% to the 40-45% target?
Answer, Rakesh Mahajan, Advisor. Q4 API improvement driven by volume ramp; API prices at bottom for last 2-3 quarters and not expected to be sustainable. On exports, IOL has regulatory approvals for non-Ibu in Europe, Brazil, Russia, Korea and China — hopeful of 40-45% export share in next 2 years. Chemical export share rose to 18% in FY25 from 10-12% earlier, aided by ethyl acetate recertification; acetic anhydride CEP from Europe in process.
6. USFDA inspection and greenfield product plan
Raj Patel, RK Securities
Question. Has there been any communication on when the USFDA site visit might occur? What is the product portfolio plan for the Chandigarh-Bathinda greenfield facility and the status of regulatory approvals and site readiness?
Answer, Kushal Kumar Rana, Director Works. USFDA inspection is entirely the agency's prerogative; company is ready. Recently got US approval for Fenofibrate DMF after responding to queries. On greenfield, environmental clearance, NHI permissions and Pollution Control Board approvals are under process; planned product line is same — chemicals and APIs with some forward integration to DC grade semi-finished products.
Not answered directly.
7. Backward integration roadmap and FY26 capex
Vivek Gupta, Star Investments
Question. Which additional APIs are being considered for backward integration and how will investments be sequenced? What is the capex plan for FY26 and any major new areas?
Answer, Kushal Kumar Rana, Director Works. R&D is working on backward integration for existing products; will share specifics at the appropriate time. FY26 capex planned at INR150-200 cr (similar to last 2-3 years), including growth capex, infrastructure, automation and development.
Not answered directly.
8. Cost structure, export trajectory, patents and FY26 margin guidance
Shaikh Mohammed Ayyaz, Individual Investor
Question. Other expenses dropped from INR81 cr to INR65-70 cr — where do we see them settling? What was the export % in FY23 vs 27% in FY25? Can you share chemical segment export % and previous figures? Any update on patents including the Edoxaban filing? Status of Mesalazine and Quetiapine CEPs? Any EBITDA margin guidance for FY26?
Answer, Rakesh Mahajan, Advisor. Other expenses include power and fuel — rice-based fuel prices dropped drastically in FY25; current year planned at similar levels (around INR65-70 cr). FY23 export share was 29-30% — came down to 27% due to European underutilisation from Ukraine war and lower API prices (volumes actually up). Chemical export share rose to 18% from 10-12%. Three patents approved, no Edoxaban patent confirmed. Mesalazine and Quetiapine CEPs secured; being planned for multiproduct facility before commercial scale-up. FY26 EBITDA margin expected >15% (vs 13% in Q4 FY25).
Follow-up. What EBITDA margin guidance for FY26 given the decline from 12% to 11% to 10.7%?
Answer. Q4 FY25 EBITDA margin was ~13%; expecting more than 15% in the current year.
9. API pricing reversal, segment mix, plant incident and FY26 growth
Maulik, B&K Securities
Question. For which products are we seeing price trend reversal apart from Paracetamol? What is the Ibu/non-Ibu split for Q4? Has the minor plant leakage been sorted? Any USFDA inspection intimation? What revenue growth is expected for FY26 — volume or value driven?
Answer, Abhay Raj Singh, SVP & Company Secretary. Clopidogrel, Fenofibrate and Pantoprazole seeing volume and slight price improvement; everything stable last 2-3 quarters, except Paracetamol. Q4 Ibu/non-Ibu split is 65/35. The leak was a minor 10-15 minute reaction issue contained within a single plant — no material impact. No inspection intimation received. FY26 revenue growth expected at 10-15% — mix of volume and prices.
Follow-up. Has the plant leak been sorted and any revenue loss?
Answer. It was a very minor 10-15 minute leakage attended immediately; contained within single plant; no prolonged effect.
10. Chemical margin drivers and Ibuprofen vs non-Ibu margin profile
Vikas Doshi, KR Investments
Question. How do you break down the chemical segment EBIT improvement in Q4 — was it cost control, process optimisation or scale efficiencies? How do Ibuprofen margins compare with non-Ibu API portfolio — do molecules like Paracetamol, Metformin, Clopidogrel offer stronger margin support?
Answer, Abhay Raj Singh, SVP & Company Secretary. Chemical EBIT improvement was primarily from scale efficiency — maximum quantity in Q4 for both ethyl acetate and acetic anhydride. Ibuprofen margins currently higher than non-Ibu, but other non-Ibu products are potentially equivalent or better on EBITDA margin once they get more revenue from regulated markets — that is the active exploration.
11. Acetic anhydride and Paracetamol demand recovery
Appu Rafi, Individual Investor
Question. Acetic anhydride and Paracetamol demand has been sluggish — how are demand trends evolving currently? Any recovery in these segments? Is this a gradual recovery that won't fade like before?
Answer, Rakesh Mahajan, Advisor. Acetic anhydride prices stable. Paracetamol demand and price expected to improve with the current geographical scenario. Existing 3,600-ton plant was running near full capacity — demand is there, but price was the issue. Expecting demand and price to remain in the global market.
Partly answered.
12. DCDA, competition, Paracetamol capacity clarification and Metformin US status
Hemant Kanungo, Norasia
Question. Any plans to manufacture DCDA given the backward integration philosophy? Any competitive challenges from new players in Ibuprofen? Is the current Paracetamol capacity 13,000 tons or 10,000 tons? Is Metformin USFDA approved?
Answer, Abhay Raj Singh, SVP & Company Secretary. No plans for DCDA currently — basic input material demand-supply issues. New players in Ibuprofen not a major concern as of now — IOL relies on operational efficiency, quality and marketing. Paracetamol effective capacity is 10,800 MTPA (new plant); old 3,600 MTPA plant production will be shifted and the old plant repurposed for other products. Metformin: one of IOL's customers filed ANDA referencing IOL and it got approved, allowing customer to sell in US — hence marked as approved.
Follow-up. Is the Paracetamol capacity 10,000 or 13,000 tons?
Answer. Effective capacity is 10,800 MTPA from the new plant; old 3,600 MTPA plant production will be shifted to the new one and the old plant will be repurposed for other products.
What was said
Topic by topic, in the order it was spoken
Industry Context and Strategic Positioning · Abhay Raj Singh (SVP & Company Secretary)
- FY25 saw mixed trends — pharma demand stable but pricing pressure from global oversupply and aggressive Indian entrants weighed on industry margins
- Management frames IOL's chemicals business as captive enabler of API cost efficiency rather than a stand-alone cyclical exposure
- Some merchant chemicals (notably ethyl acetate) exposed to global destocking commentary
Q4 FY25 Operational and Portfolio Highlights · Abhay Raj Singh (SVP & Company Secretary)
- Q4 saw improved Ibuprofen traction despite continued price challenges; broader API basket stable on demand and pricing
- Backward-integrated Paracetamol unit commissioned at Barnala — INR155 cr funded entirely from internal accruals
- Paracetamol capacity raised to 10,800 MTPA, strengthening non-Ibu portfolio which is now 34% of API revenue (up from 18% five years ago)
- Clopidogrel capacity expanded by 33%; Ibuprofen China CDE approval cited as a key milestone for global reach
- 101 acres acquired on Chandigarh-Bathinda Highway for greenfield expansion; environmental and NHI clearances under way into FY26
Q4 and FY25 Financial Performance · Pardeep Khanna (CFO)
- Q4 FY25 revenue from operations at INR528 cr (+4.7% YoY); FY25 revenue at INR2,079 cr
- Q4 EBITDA at INR67 cr (+17% YoY), margin 12.7% (+141 bps); FY25 EBITDA at INR225 cr at ~11% margin
- Q4 PAT at INR31.6 cr (+12% YoY), margin 5.9% (+43 bps); FY25 PAT at INR101 cr at 4.8% margin
- Cash PAT highlights the depreciation drag: Q4 cash PAT at INR56.4 cr (+15% YoY); FY25 cash PAT at INR185 cr
- Net debt-to-equity at 0.09 — minimal leverage, ample headroom for growth capex
Regulatory, Backward Integration and Export Strategy · Abhay Raj Singh (SVP & Company Secretary)
- Therapeutic diversification across antidiabetics, analgesics, anticholesterol, antiepileptic and cardiovascular categories
- 16 DMFs and 19 CEPs filed as foundation for global presence; export revenues currently 27%
- Backward integration model positioned as the central margin-resilience lever — cost, quality, supply security
- Management tone frames FY25 as a year of 'consolidation, efficiency gains and strategic investments'
In their words
Cash PAT for quarter 4 of '25 stood at INR56.4 crores compared to INR49.2 crores in quarter 4 of financial year '24, an increase of about 15%. For the full financial year '25, cash PAT was INR185 crores underscoring our strong cash generation and the resilience of our core operations.
Actually, we are unable to comment how the others are doing. But as you know that for the Ibuprofen, we are the backward integrated facility and we command the backward chain also and we are considered as one of the best cost-efficient company for the Ibuprofen. So that is the reason we are able to generate the better efficiency and on a sustainable basis having around 85% to 90% capacity utilization.
We are entering financial year '26 with sharper execution focus, deeper capabilities and a clear road map for scaling in both domestic and regulated international markets.
To check next time
What management committed to on this call, or the dates they gave.
- Execution toward guided EBITDA margin above 15% in FY26.
- FY26 revenue growth delivery against 10-15% guidance.
- FY26 capex deployment of INR150-200 crores.
- Paracetamol demand and price trajectory after soft FY25.
- Progress on chemicals EBITDA margin toward ~10% target.
- U.S. FDA inspection scheduling for Barnala site; export ramp into China for Ibuprofen.
Transcript
We have not transcribed this call's recording. Read the company's transcript (PDF).
The stock after the call
| After the call | Close | Stock | Nifty 50 |
|---|---|---|---|
| Next session Tue 20 May 2025 | ₹79.15 | −2.76% | −1.05% |
| 5 sessions Mon 26 May 2025 | ₹87.17 | +7.09% | +0.22% |
| 20 sessions Mon 16 Jun 2025 | ₹88.93 | +9.25% | 0.00% |
From the close of Mon 19 May 2025, ₹81.40: the close before the call day (the call's time is not on file). Adjusted daily closes; the move includes everything else that happened in those sessions.